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ORIGINAL RESEARCH
Prescribing of Antipsychotic Medication in a Medicaid Population:
Use of Polytherapy and Off-Label Dosages
STEPHEN J. KOGUT, PhD, MBA; FELIX YAM, PharmD; and ROBERT DUFRESNE, PhD, PhD, BCPS, BCPP
he atypical antipsychotic medications have rapidly
become a leading drug expense category within
Medicaid populations, which typically serve lower-
income citizens, institutionalized seniors, and the disabled.
Many patients within this population have psychiatric illnesses
for which antipsychotic medications are commonly prescribed.
The U.S. Food and Drug Administration (FDA) has approved
the atypical antipsychotic medications for use in the treatment
of schizophrenia (all atypicals) and bipolar disease (olanzapine,
risperidone, and ziprasidone only), yet these agents are 
commonly prescribed “off-label” for a variety of other conditions,
particularly where psychosis is a feature. 
Despite a substantial difference in the direct cost of these
medications compared with the conventional antipsychotics,
several researchers have found the atypicals to be at least as cost
effective as the conventional antipsychotics.1-5 These medica-
tions also provide advantages in terms of decreased motoric side
effects such as drug-induced parkinsonism, tardive dyskinesia,
and akathesia6,7 and improved efficacy in treating negative 
symptoms of schizophrenia such as avolition (absence of initiative
or motivation to begin and maintain behavior in pursuit of a
goal) and flat affect.8-10 Also, the newer agents have shown
advantages in terms of improvement in health-related quality of
life.11-13 These medications have also been shown to be cost
effective.2-4,14 However, pharmacoeconomic studies have evaluated
the cost-effectiveness of various atypical agents when adminis-
tered in dosages used in clinical trials and as approved by the
FDA. The cost-effectiveness of the atypical antipsychotics when
used in combination therapies or when prescribed at dosages
above or below the recommendations described in the product
labeling has not been well studied.  
While physicians may legally prescribe medication at
dosages outside of the parameters recommended in the product
ABSTRACT
OBJECTIVES: To describe the use of atypical antipsychotic medications in a
Medicaid-enrolled population composed primarily of elderly and disabled
patients. Our analyses focused upon the frequency of use of polytherapy with
multiple antipsychotic medications and the prescribing of off-label dosages. 
METHODS: We conducted a cross-sectional retrospective analysis of oral 
antipsychotic medication use, as prescribed for this population in 2003. The unit
of analysis was the patient. We determined the prevalence of use of each type of
antipsychotic medication according to gender and age group and determined the
extent of use of combination therapies with multiple oral antipsychotic medications.
Using the dosage ranges described in the product labeling, we identified the 
percentage of patients prescribed in-range dosages, overall and for each atypical
antipsychotic medication studied. Those identified as receiving out-of-range
(off-label) dosages were further stratified by gender and age group. The statistical
significance of differences between these proportions was assessed using the
chi-square test. 
RESULTS: Of the 8,616 patients meeting our inclusion criteria, 7,748 (90%)
received monotherapy with an oral antipsychotic medication and 868 patients
(10%) received polytherapy with multiple oral antipsychotic medications.
Approximately 2 of 3 patients receiving atypical antipsychotic medications were
prescribed a dosage that was within the range recommended in the product
labeling. Dosages lower than recommended in the product labeling were 
prescribed for 27% of patients receiving atypical antipsychotics, while 6% of
patients received an above-range dosage. The frequency of patients receiving 
in-range dosages varied substantially among medications. Younger patients and
male patients were more frequently prescribed above-range dosages while older
patients and female patients were more frequently prescribed below-range
dosages of these medications (P<0.001 for both findings).
CONCLUSION: In this subpopulation of Medicaid enrollees who were prescribed 
antipsychotic medications, we found a 10% incidence of use of antipsychotic poly-
therapy and a 33% incidence of prescribing of dosages outside the range listed in
the product labeling. These findings suggest that physicians commonly prescribe
antipsychotic medications in a manner that differs from the recommendations
described in the prescribing information. The off-label use of atypical antipsy-
chotic medications raises important questions regarding the purpose and 
applicability of the product labeling and the role and ability of the pharmacist to
provide information regarding the risks and benefits of therapy as commonly 
prescribed.
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labeling, the safety and efficacy of a medication as evaluated by
the FDA generally does not extend to off-label usage. Recent
reports describing antipsychotic medication use in current 
practice settings reveal a high prevalence of combination therapy
with multiple antipsychotic medication regimens15-17 and the
use of high-dose therapies.18-20 Although randomized 
placebo-controlled trials are lacking, therapies that combine
antipsychotic medications may hold promise for certain patient
subtypes,21-24 and growing evidence suggests a benefit of 
high-dose therapy for some patients with treatment-resistant 
disease.25,26 However, studies describing the dose-response 
relationship pertaining to the efficacy and toxicity of the atypical
antipsychotics are lacking.27
Higher dosages of atypical antipsychotic medications may
provide benefit for a percentage of patients who do not respond
to recommended dosages, but the risk associated with using
higher dosages of an atypical antipsychotic medication has not
been as well studied. Additionally, the use of below-range
dosages of the atypical antipsychotics merits examination.
Though prescribers may act from concern regarding the use of
these potent medications in elderly or frail individuals, the use
of low-dose therapy may nevertheless cause adverse effects
while failing to elicit a worthwhile therapeutic response. 
The objective of our study was to assess the manner in which
atypical antipsychotic medications are prescribed in a Medicaid
population comprising mainly elderly and disabled patients. We
sought to determine the extent of use of combination oral
antipsychotic therapies and the prevalence of prescribing off-label
dosages. We compared dosages of the atypical antipsychotics as
prescribed among older and younger patients, among genders,
overall, and for specific agents. We did not presume that the 
prescribing of off-label dosages was inappropriate per se; rather,
our aim was to better understand how these medications are 
prescribed and to identify opportunities for improving and studying
the efficacy of the use of these medications in the population.
 Methods 
We conducted a cross-sectional study of antipsychotic medication
use among Rhode Island Medicaid enrollees to describe the use
of antipsychotic medications as most recently prescribed for
patients during 2003. The state of Rhode Island provides a
managed care insurance program that serves a proportion of
nonsenior residents who are eligible for the program based upon
low income (categorically needy). A majority of Medicaid-eligible
senior and nonsenior disabled patients receive their care through
a fee-for-service program component that is administered by the
state’s Department of Human Services. This fee-for-service 
population comprised the universe of patients available for our
study. Our analyses were conducted solely using pharmacy
claims data, which included patient age, gender, and information
pertaining to the dispensed prescription. The Rhode Island
Medicaid pharmacy program does not restrict the use of
antipsychotic medications, nor are any particular medications
considered preferred. 
The unit of analysis was the patient. There were 59,498
patients enrolled in the fee-for-service component and receiving
prescription medication during 2003. Seniors (aged 65 years or
older) comprised 31% of the population. Among patients
receiving prescription medications, 10,470 (18%) received at
least 1 dispensing for an oral antipsychotic medication during the
study year. We chose to exclude patients who were initiating
therapy and selected only those patients who received at least 
3 dispensings for an oral antipsychotic medication (n=8,761). This
total does not include patients receiving an antipsychotic 
medication in liquid form (n=1,505); these patients were excluded
because we could not reliably calculate the dosage prescribed for
liquid products given the limitations of our data source.
Additionally, we excluded 63 patients who received 
an injectable product as their most recent dispensing of an 
antipsychotic medication. 
We also attempted to distinguish users of combination
antipsychotic therapy (polytherapy) from patients who were
switching therapies. Patients were classified as users of 
polytherapy if they received at least 2 dispensings of the 
2 different antipsychotic medications during the 90 days prior
to the most recent dispensing. All other patients receiving more
than 1 type of oral antipsychotic medication were considered to be
recent switchers and were excluded (n=83). The resulting sample
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Selection of Patients for Analyses 
of Types of Antipsychotic Medication
Regimens Utilized and for Analyses 
of Prescribed Dosages of Atypical
Antipsychotic Medications  
FIGURE 1
N
59,498 Medicaid enrollees in fee-for-service component receiving at
least 1 prescription dispensing during 2003
↓
10,470 Patients receiving at least 1 prescription dispensing for any 
(17.6%) type of antipsychotic medication
↓
8,698 Patients receiving at least 3 prescription dispensings for an oral
(14.6%) solid (excluding nonliquid) antipsychotic medication
↓
8,616 Patients who were not recently switching antipsychotic drug
(14.5%) therapy (within past 90 days)
↓ • Study population for analyses of types of antipsychotic
medication regimens prescribed
7,759 Patients who were users of risperidone, olanzapine, quetiapine,
(13.0%) aripiprazole, or ziprasidone 
• Study population for analyses of dosages prescribed of 
atypical antipsychotic medications
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of 8,616 patients comprised the population of study for the
analyses of frequencies of use of various oral antipsychotic 
regimens. The sample selection criteria and totals of patients
identified are presented in Figure 1.
We determined the prevalence of use of specific 
antipsychotic medication regimens based upon the most recent
dispensing for such products occurring during the study year.
Patients identified as receiving antipsychotic polytherapy were
categorized as either receiving polytherapy with an atypical plus
a conventional antipsychotic medication or polytherapy with 
2 different atypical antipsychotic medications. The prevalence of
use of polytherapy was stratified by gender and by age group (age
less than 18 years, age 18 to 64 years, and age 65 years or older). 
The percentage of therapies used in off-label dosage was
determined for patients receiving atypical antipsychotic 
medications, as attributed to the dosage of the most recently 
dispensed prescription during the year. For this prescription, we
calculated the mean daily dose by dividing the quantity of 
medication dispensed by the days supply received and multiplying
this quotient by the strength (in milligrams) of the dispensed
medication.  Recommended dosages for each atypical medication
were identified from the prescribing information as obtained
from each manufacturer’s Web site (accessed in June 2004).
Where the dosage range varied by indication, age, or clinical
condition, we used the lowest and highest possible range of
dosages that appeared in the product labeling. FDA-
recommended in-range dosages as described in the product
labeling were as follows—aripiprazole: 10 to 30 mg, quetiapine:
150 to 750 mg, olanzapine: 5 to 20 mg, risperidone: 1 to 8 mg,
and ziprasidone: 14 to 160 mg. We did not include patients
receiving clozapine in these analyses because we believed that
those receiving this medication were more likely to have severe
disease and/or have failed other therapies and because this 
medication was often dispensed in a 1-week supply, a feature
that added considerable complexity to the analyses. 
Several patients were prescribed “odd” dosages of medication
and received different prescriptions for the same medication 
(e.g., 2 mg of risperidone in the morning and 3 mg at bedtime).
Such patients were included in our analyses if the two prescriptions
for different strengths of the same medication were received on 
the same date during the two most recent dispensings. For these 
281 patients, we calculated the total dose by adding the daily
dosages of the two separate prescriptions. 
We determined the frequency and percentage of patients
receiving dosages below or above the recommended range,
overall, and for users of each particular atypical antipsychotic
agent. The frequency and percentage of patients receiving
below- or above-range dosages were stratified by gender and
age group (seniors versus those younger than 65 years).
Differences in the proportions of males and females receiving 
off-label dosages was evaluated through cross-tabulation, and the
statistical significance between differences in these proportions
was determined using the chi-square test. Differences in the
proportion of senior and nonsenior patients receiving off-label
dosages were assessed in the same manner. The level of 
significance was set at P<0.05, with a minimum of 5 observations
per cell required for reporting probabilities. These analyses were
performed using SAS version 8.1 for microcomputers.
  Results
Of the 59,498 Medicaid fee-for-service program enrollees
receiving prescription medication during 2003, nearly 1 in 5
received a dispensing for an antipsychotic medication. A total of
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Frequency and Percentage of Use of
Antipsychotic Medications Within a
Medicaid Population: Overall Use and 
Use of Polytherapy, Stratified by Gender
and Age Group
TABLE 1
Frequency and Percentage of Use of
Atypical Antipsychotic Medications and
Conventional Antipsychotics Prescribed 
as Monotherapy or Polytherapy
TABLE 2
Patients % Using % Using
Prescribed Polytherapy: Polytherapy
Antipsychotic % Using Atypical + Atypical 
Medication* Polytherapy† Conventional  + Atypical
n % n % n % n %
Gender
Male 3,685 42.8 455 12.3 93 2.5 362 9.8
Female 4,931 57.2 413 8.4 87 1.8 326 6.6
Age (years)
<18 554 6.4 25 4.5 4 0.7 21 3.8
18-64 5,477 63.6 710 13.0 152 2.8 558 10.2
65+ 2,585 30.0 133 5.1 24 0.9 109 4.2
Total 8,616 100 868 10.1 180 2.1 688 7.9
* Received at least 3 dispensings for an oral antipsychotic medication during 2003.
† Polytherapy = concomitant use of 2 or more different antipsychotic medications.
n %
Monotherapy
Risperidone 2,283 26.5
Olanzapine 2,275 26.4
Quetiapine 1,756 20.4
Aripiprazole 382 4.4
Clozapine 346 4.0
Ziprasidone 195 2.3
Conventional agent 511 16.0
Subtotal =7,748
Polytherapy
Atypical + conventional 180 2.1
Atypical + atypical 688 8.0
Subtotal =868
Total 8,616 100
Non-commercial academic use only.
8,616 patients met our criteria of receiving at least 3 dispensings
for any oral, nonliquid antipsychotic medication during the
year, a majority of which were nonsenior adults (64%). The use
of polytherapy with multiple antipsychotic agents was more 
frequent among males for both polytherapy with atypical or 
conventional agents. The use of polytherapy was also more 
frequent among nonsenior adults than among seniors (13% versus
5%). These results are presented in Table 1. 
Of the patients meeting our study criteria, 7,748 (90%) were
identified as receiving monotherapy with an antipsychotic 
medication, and 7,327 (94%) of these patients were receiving
monotherapy with an atypical antipsychotic medication.
Approximately three quarters of patients receiving antipsychotic
medication were users of monotherapy with risperidone, 
olanzapine, or quetiapine. Of the approximately 10% of patients
identified as receiving polytherapy, the majority (688 of 868, or
79.3%) received 2 atypical antipsychotic drugs, while 2.1% of
all patients received polytherapy with an atypical plus a 
conventional antipsychotic medication (21% of patients who
received polytherapy) (Table 2).
Figure 2 presents dose range categories for the prescribed
dosages of atypical antipsychotic medications regardless of
whether the medication was used alone or in polytherapy with
another antipsychotic agent. Overall, approximately 1 in 3
patients was prescribed an atypical antipsychotic medication at a
dosage that was not within the recommended range. The majority
of off-label dosing was for below-range dosages, as 27% of
patients received medication at a dosage that was below the
range recommended in the product labeling. In-range dosing
was more frequent among users of aripiprazole (94%) and
ziprasidone (85%) as compared with the other atypical anti-
psychotic medications. Quetiapine was prescribed within the 
recommended range least frequently; users of this medication
received below-range dosages as frequently as they received 
in-range dosages (47%). Use of below-range dosages was next
most frequent among users of risperidone (25%) and then 
olanzapine (17%), with 7% of ziprasidone users and 5% of 
aripiprazole users receiving below-range dosages. 
Use of above-range dosages was much less frequent than the
use of below-range dosages. Overall, 6% of patients received 
medication at dosages that were higher than recommended in the
product labeling. The percentage of patients receiving above-
range dosages was 9.5% for olanzapine, 8% for ziprasidone, 
6% for quetiapine, 3% for risperidone, and 2% for aripiprazole.
For patients receiving above- or below-range dosages, we
determined if the use of such dosages was more frequent among
particular age groups or by gender. These stratifications are 
presented for those receiving above- and below-range dosages
in Figures 3 and 4, respectively. Patients receiving above-range
dosages were overall more frequently male and younger than 
65 years (P < 0.001 for both). Male and nonelderly patients were
also more frequently prescribed above-range dosages of olanzapine
and quetiapine as compared with female or senior patients,
respectively. Each of these findings was statistically significant.
The use of above-range dosages of risperidone, ziprasidone, or
aripiprazole did not differ in statistical significance among age
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Percentage of Patients Receiving 
Below, Above, or Within-Range Dosages 
of Atypical Antipsychotic Medications 
FIGURE 2
Percentage of Patients Receiving Above-
Range Dosages of Atypical Antipsychotic
Medications: Results Presented by Age
Group and Gender 
FIGURE 3
100
90
80
70
60
50
40
30
20
10
0
Risperidone Olanzapine Quetiapine Aripiprazole Ziprasidone Overall
(n=2,580) (n=2,486) (n=2,021) (n=460) (n=212) (n=7,759)
Overall 
(n = 7,759)
Ziprasidone 
(n = 212)
Aripiprazole
(n = 460)
Quetiapine 
(n = 2,021)
Olanzapine 
(n = 2,486)
Risperidone 
(n = 2,580)
P <0.001
P <0.001
n/a
n/a
n/a
n/a
P =0.018
P <0.001
P <0.001
P <0.001
P =0.22
n/a
0 10 20 30 40 50 60 70 80
n/a = numbers too small for reporting results of statistical test (n < 5).
In-range dosages for aripiprazole: 10-30 mg, quetiapine: 150-750 mg, olanzapine:
5-20 mg, risperidone: 1-8 mg, and ziprasidone: 14-160 mg.
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Female
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Age 65 +
Age < 65
%
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groups or by gender, though in most cases these subgroups
were too small to analyze. 
In contrast to patients receiving above-range dosages of
these medications, users of below-range dosages were more 
frequently female and above age 65 years (P < 0.001 for both).
Quetiapine, the agent most frequently prescribed in below-range
dosages, was prescribed in below-range dosages for 72.5% of 
seniors using this medication. While seniors were more frequently
prescribed below-ranges dosages of quetiapine as compared 
with nonsenior patients (72.5% versus 40%, P < 0.001), the 
percentage of males (47%) and females (50%) prescribed
below-range dosages of this medication did not differ in 
statistical significance. For each of the atypical antipsychotics,
seniors were more frequently prescribed below-range dosages
than nonsenior patients, though the percentage of use of below-
range dosages among seniors varied considerably among 
medications. Slightly more than half of senior patients (51%)
receiving risperidone were prescribed a dosage that was below
the recommended range. This proportion was substantially
greater than the percentage of below-range dosages prescribed
for seniors using ziprasidone (21%) or aripiprazole (12%). Use
of below-range dosages of quetiapine, ziprasidone, and 
aripiprazole was similar among males and females, while
females were more likely than males to receive below-range
dosages of olanzapine or risperidone (P < 0.001 for both findings). 
 Discussion
In this population of Medicaid-enrolled seniors and disabled
patients, we found a high rate of prescribing of antipsychotic
medications in off-label dosages. Most of such prescribing was for
dosages below the recommended range, though approximately
6% of patients received dosages that were above the range 
recommended in the product labeling. 
As may be expected, seniors were more frequently 
prescribed below-range dosages, while above-range dosages
were more frequently prescribed for nonsenior patients. This
trend, observed for all of the atypical antipsychotic agents 
prescribed, may likely be mainly attributed to the condition for
which the medications were prescribed. It is probable that younger
patients were more frequently prescribed these medications for the
treatment of schizophrenia or bipolar disorder, while older
patients may have more frequently received these medications
for off-label conditions such as psychosis or agitation, where
lower dosages are commonly prescribed. We note, however,
that we did not possess information describing patient diagnoses,
and, hence, this interpretation is largely speculative. While we
did not examine diagnosis codes to attempt to determine the
conditions for which these medications were prescribed, our 
primary objective was to quantify the extent of off-label dosing
regardless of the condition being treated. Furthermore, the 
reliability of using diagnosis codes from medical claims to identify
schizophrenia and related disorders may be questionable.28,29
Though not specifically recommended in the product labeling
or in current treatment guidelines for schizophrenia30 or bipolar
disorder,31 the use of polytherapy with multiple atypical
antipsychotic medications has been identified as an increasingly
common practice.15,17,32,33 Thus, we were not surprised to find
that many patients were receiving multiple antipsychotic 
medications concomitantly. Indeed, the use of antipsychotic
polytherapy was quite common in the population, particularly
among younger patients. Roughly 1 in 10 nonelderly patients
received therapy with multiple atypical antipsychotics. It is 
possible that some of these patients were transitioning to different
therapies, though we did attempt to exclude patients who were
switching therapy, as described above.
Though several reports from smaller trials provide evidence
to support the potential effectiveness of antipsychotic polytherapy
for patients with treatment-resistant disease,21,22,34 no atypical
antipsychotic has gained FDA approval for use in combination
with other atypicals. Furthermore, the American Psychiatric
Association’s treatment guidelines for schizophrenia30 do not 
support the use of polytherapy as routine practice. While the use of
antipsychotic polytherapy was found to be fairly common in the
population studied here, limited information is available regarding
the safety of using multiple antipsychotic medications 
concomitantly. When used as monotherapy, these agents are
known to cause potentially significant adverse effects. Many of
these agents have been found to increase plasma glucose levels,35
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Percentage of Patients Receiving Below-
Range Dosages of Atypical Antipsychotic
Medications: Results Presented by Age
Group and Gender 
FIGURE 4
Overall
(n=7,759)
Ziprasidone
(n=212)
Aripiprazole
(n=455)
Quetiapine
(n=2,021)
Olanzapine
(n=2,486)
Risperidone
(n=2,580)
P <0.001
P <0.001
P =0.76
n/a
P =0.07
P <0.001
P <0.001
0 10 20 30 40 50 60 70 80
In-range dosages for aripiprazole: 10-30 mg, quetiapine: 150-750 mg, olanzapine:
5-20 mg, risperidone: 1-8 mg, and ziprasidone: 14-160 mg.
P =0.5
P =0.01
P <0.001
P <0.001
P <0.001
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Male
Age 65 +
Age < 65
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Non-commercial academic use only.
22    Journal of Managed Care Pharmacy JMCP January/February 2005 Vol. 11, No. 1 www.amcp.org
body weight,36-38 and serum triglycerides.39-42 The atypical anti-
psychotic medications are associated with other problematic side
effects. To varying degrees, these agents can cause sedation,
anticholinergic side effects,43 and QTc prolongation.44 However
little is known about the prevalence and severity of these side
effects when atypicals are used in greater than recommended
dosages or in combination with each other. At the very least, the
benefit-to-risk ratio should be reconsidered when polytherapy is
initiated. However, there is a paucity of larger and long-term
clinical trials of the use of antipsychotic medications in higher
dosages or in combination. 
While high doses of atypical antipsychotic agents may be
incrementally effective for treatment-resistant patients, the 
evidence supporting this use is primarily drawn from smaller
studies that do not adequately assess the frequency and extent
of adverse events likely to be experienced. For example, Lerner
et al.25 describes the effectiveness of high-dose olanzapine as 
prescribed for 3 patients with treatment-resistant schizophrenia,
while Brotman et al.26 presents a case series of 8 patients receiving
high-dose therapy. High-dose therapy may be a useful option
for selected patients, yet the relative lack of information pertaining
to the safety of such dosages is of concern. It was encouraging
in our study to find a small percentage of elderly patients (less
than 1%) who received higher dosages of antipsychotic 
medications, but nearly 8% of nonelderly patients received atypical
antipsychotic medication in dosages above the recommended
range. This suggests that the use of high-dose therapy in younger
adult patients is fairly common, at least within this Medicaid 
subpopulation.
Though the use of below-range dosages may be of lesser 
concern in terms of the safety and risks of therapy, one may ques-
tion the rationale for using these medications in potentially 
subtherapeutic dosages. The in-range dosages applied in our
analyses included dosages recommended for frail and elderly
patients. As such, patients identified as using below-range
dosages were prescribed medication in dosages that were below
what was found to be efficacious in the clinical trials upon
which the FDA-approved labeling is based (though such trials
generally do not include frail and/or elderly patients). Perhaps
prescribers were merely exerting caution when using these agents
in elderly patients. Lower dosages of atypical antipsychotics are
associated with a reduced incidence of motoric side effects such
as tardive dyskinesia,45 but placebo-controlled trials demonstrating
the efficacy of low-dose therapy in the treatment of schizophrenia
or bipolar disease are lacking. 
It is possible that many elderly patients in the population we
studied received these medications in low dosages for off-label
indications such as agitation or insomnia. This may be particularly
true for the use of quetiapine, which was prescribed in 
below-range dosages for nearly 3 of 4 seniors receiving this
medication. We also considered the possibility that patients
receiving low-dose therapy may have been more likely to be users
of polytherapy. However we found the converse to be true—
patients prescribed below-range dosages of atypical antipsychotics
were less likely to be receiving multiple antipsychotic agents than
were users of higher dosages (6% versus 13%, P <0.001). 
Overall, these findings provide evidence that the FDA-approved
labeling describing the indications and recommended dosages
of these agents appears to correspond poorly with how atypical
antipsychotics are prescribed in practice. Yet it is important to
note that our findings do not necessarily indicate that medications
were prescribed inappropriately. It may be argued that the 
off-label use of medications reflects emerging knowledge and
that the product labeling may fail to keep pace with new findings
pertaining to the scope or utility of medications. 
The FDA’s supplemental new drug approval (sNDA) process
provides a mechanism for updating the product labeling to include
new indications and updated dosages. However, the costs 
associated with the submission of an sNDA may present a 
disincentive to manufacturers, especially when a new indication or
dosage pertains to a smaller subpopulation of potential medication
users. Furthermore, the efficacy of the medication for a new use or
dosage may fail to be substantiated when subjected to the rigorous
study required for submission of an sNDA, creating a disincentive
for manufacturers to submit such an application. The need for 
a manufacturer to obtain an sNDA is lessened further when
physicians rely upon personal experience and the opinions of 
others when prescribing medications. Thus, at least partially as a
consequence of the above considerations, there exists a complex
dynamic between the FDA-approved usage of a medication versus
published evidence from recent trials and experience gained from
prescribing a medication in practice.
The off-label prescribing of these medications presents 
important issues from the perspectives of the practicing pharma-
cist and for those responsible for the pharmacy benefit. The 
practicing pharmacist must be aware that the risks described in
the product labeling directly pertain to the use of the medications
for approved indications and when prescribed at recommended
dosages. The use of polytherapy with multiple antipsychotic
medications or the prescribing of above-range dosages warrants
careful consideration of the potential for benefits and risks. The
dispensing pharmacist can provide a service to prescribers and
other members of the health care team by making them aware of
patient cases in which the prescribed therapy is considered to be
off-label and by alerting providers to the need for increased atten-
tion to monitoring for effectiveness and signs of adverse reactions.
The implications for those responsible for providing the 
pharmacy benefit are less straightforward. The atypical 
antipsychotics are an expensive class of medications, but these
drugs have become common in the care for patients with 
psychosis, and can be cost effective when used appropriately.
How then should these medications be used most appropriately
within a population? Some may interpret “appropriate use” as
the prescribing of these products only for labeled indications
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and at recommended dosages. Formulating policy upon such
an interpretation may prove to be difficult given the extent of
off-label usage as described here and by others. Most importantly,
such a policy is not likely to benefit patients when off-label uses
offer a therapeutic advantage. Nevertheless, one may question if
the pharmacy benefit should provide for the use of expensive
therapies that have not been assessed for safety and effectiveness.
The use of such therapies may be justified where off-label 
regimens benefit patients more than they harm them, but it is
often not possible to know a priori when this might be the case. 
Analyses such as the type described here can provide the
basis for interventions designed to align prescribing within
appropriate dosing parameters, as determined through review of
the available evidence, and by collaborating with clinicians having
expertise in the use of these medications. Such interventions may
potentially include provider profiling, academic detailing, or
other educational initiatives designed to inform prescribers about
the risks and benefits of the off-label use of these medications. 
Another approach is to require that appropriate diagnoses
exist prior to initial prescription. Policy makers must be careful
when developing criteria for such a strategy, since the use of
atypical antipsychotic medications for off-label conditions may
offer a meaningful therapeutic benefit for certain patients. 
Lastly, we note that on-screen edits alerting the pharmacist to
the prescribing of off-label dosages can be helpful for identifying
dosage errors and prompting the pharmacist to contact the 
prescriber to ensure that the proper medication dosage is 
prescribed. While the prescriber may ultimately decide which
medication dosage is employed, a clinically sound and 
well-managed system for utilizing these medications within the
parameters of the pharmacy benefit will aid in ensuring that 
the inappropriate use of these medications is minimized. 
Limitations 
Our research included several limitations that should be
acknowledged. Most important, pharmacy claims were our sole
data source, and we did not determine the conditions for which
these medications were prescribed. It is possible that our results
may be biased by inaccuracies in the pharmacy claims data. For
example, since we did not audit or otherwise verify the dosages
of medication prescribed (e.g., through review of medical
charts), it is possible that inaccurate values in pharmacy claims
for the days supply or quantity of medication dispensed were a
source of error. Also, we did not determine the duration of use
of these medications and dosages. 
Though our inclusion criteria specified that patients must have
received at least 3 dispensings of antipsychotic medication, it is
possible that some patients receiving below-range dosages would
have eventually been titrated upward to an in-range dosage. 
Additionally, we did not examine other factors that may have
further explained our findings. For example, dosReis et al.18
found that African-American Medicaid enrollees more frequently
received higher dosages of antipsychotic medications than other
racial groups, while Galletly and Tsourtos found that 
schizophrenic patients receiving lithium, carbamazepine, or
benzodiazepines were more likely to receive higher dosages of
antipsychotic medications.46
Finally, we should note that our findings apply only to this
population of aged or disabled Medicaid enrollees. Generalizations
to other populations should be made with caution.
 Conclusion
In this subpopulation of Medicaid enrollees, we found that
many patients (33%) were prescribed atypical antipsychotic
medications in off-label dosages, and many patients (10%) received
multiple antipsychotic medications. These findings suggest that
physicians commonly prescribe antipsychotic medications in a
manner that differs from the recommendations described in the
prescribing information. Pharmacists have an important role in
working with the health care team to ensure that the risks and
benefits associated with the off-label use of antipsychotic 
medications are carefully considered and that patients are 
appropriately monitored. From a policy perspective, the off-label
use of atypical antipsychotic medications raises important 
questions regarding the purpose and applicability of the product
labeling, particularly in the context of current prescribing practices.
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